| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1965234 | Clinica Chimica Acta | 2015 | 5 Pages |
•Serum CEACAM1 level was significantly higher in patients with breast cancer.•Serum CEACAM1 seems to be better than CEA and CA15-3 in breast cancer diagnosis.•Serum CEACAM1 may serve as a useful indicator for the presence of breast cancer.
BackgroundCarcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a widely expressed multi-functional adhesion molecule reported to serve as a serum biomarker in several types of cancer. However, the serum CEACAM1 expression in breast cancer is unclear. We investigated the serum concentrations of CEACAM1 in patients with breast cancer and determine the potential of serum CEACAM1 as a breast cancer biomarker.MethodsSerum specimens were obtained from 33 patients with breast cancer, 30 patients with benign breast diseases and 34 healthy donors. The serum CEACAM1 concentrations were examined by an enzyme-linked immunosorbent assay (ELISA).ResultsThe serum CEACAM1 concentrations in the malignant group (532 ng/ml) were significantly higher than those of the benign group (423 ng/ml) and healthy control group (386 ng/ml) (both p < 0.001). Based on univariable logistic regression, serum CEACAM1 concentrations significantly predicted breast cancer versus normal controls or benign breast diseases. Area under receiver operating characteristic curve (ROC) for serum CEACAM1 was 0.925(95% CI: 0.866–0.984). The optimal cut-off concentration of CEACAM1 was 475.82 ng/ml for discriminating breast cancer from normal controls.ConclusionSerum concentrations of CEACAM1 may serve as a useful indicator for the presence of breast cancer.
